Outcome in Neuroblastoma

Overview

Journal Indian J Pediatr

Specialty Pediatrics

Date 2014 Oct 3

PMID 25274444

Citations 1

Authors

Ali Aykan Ozguven

Sema Anak

Aysegul Unuvar

Arzu Akcay

Zeynep Karakas

Gulyuz Ozturk

Omer Devecioglu

Leyla Agaoglu

Affiliations

Soon will be listed here.

Abstract

Objective: To determine outcome of neuroblastoma (NBL) in children under 18 mo of age who had been treated with national protocols.

Methods: The characteristics and treatment outcomes of 27 children were evaluated retrospectively.

Results: The event-free survival (EFS) at 60 and 108 mo were 84.7 % ± 7.7 and 72.6 % ± 7.7, respectively. The overall survival (OS) was 91.7 % ± 8 at 108 mo. The only significant risk factor for OS in children with neuroblastoma was the treatment response at the end of therapy (p = 0.001). "Wait and see" policy was applied to two infants with low risk NBL and one infant with stage 4S neuroblastoma and all 3 of these infants have been in remission at last followup. Four of the five patients with MYCN-amplified neuroblastoma were alive at a median follow-up time of 54 mo (range: 5-108 mo).

Conclusions: The EFS and OS of the present group were similar to that of the previous series which included children under 18 mo of age with neuroblastoma. Well known prognostic factors did not affect EFS and OS significantly; this may be related to the retrospective design of the present study and the small number of patients reviewed. High survival rate in infants with MYCN-amplified tumors suggests the difference in the biology of infant neuroblastoma.

Citing Articles

Twenty children with non-Wilms renal tumors from a reference center in Central Anatolia, Turkey.

Unal E, Yilmaz E, Ozcan A, Isik B, Karakukcu M, Turan C Turk J Med Sci. 2019; 50(1):18-24.

PMID: 31655501 PMC: 7080372. DOI: 10.3906/sag-1902-106.

References

Schmidt M, Lal A, Seeger R, Maris J, Shimada H, OLeary M . Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol. 2005; 23(27):6474-80. DOI: 10.1200/JCO.2005.05.183. View

Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J . Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol. 2009; 10(7):663-71. PMC: 3045079. DOI: 10.1016/S1470-2045(09)70154-8. View

Kim S, Chung D . Pediatric solid malignancies: neuroblastoma and Wilms' tumor. Surg Clin North Am. 2006; 86(2):469-87, xi. DOI: 10.1016/j.suc.2005.12.008. View

Tonini G, Boni L, Rogers D, Iolascon A, Basso G, Cordero di Montezemolo L . MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. J Clin Oncol. 1997; 15(1):85-93. DOI: 10.1200/JCO.1997.15.1.85. View

Nishihira H, Toyoda Y, Tanaka Y, Ijiri R, Aida N, Takeuchi M . Natural course of neuroblastoma detected by mass screening: s 5-year prospective study at a single institution. J Clin Oncol. 2000; 18(16):3012-7. DOI: 10.1200/JCO.2000.18.16.3012. View

Brodeur G, Seeger R, Barrett A, Berthold F, Castleberry R, DAngio G . International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988; 6(12):1874-81. DOI: 10.1200/JCO.1988.6.12.1874. View

Weinstein J, Katzenstein H, Cohn S . Advances in the diagnosis and treatment of neuroblastoma. Oncologist. 2003; 8(3):278-92. DOI: 10.1634/theoncologist.8-3-278. View

London W, Castleberry R, Matthay K, Look A, Seeger R, Shimada H . Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol. 2005; 23(27):6459-65. DOI: 10.1200/JCO.2005.05.571. View

Rubie H, Plantaz D, Coze C, Michon J, Frappaz D, Baranzelli M . Localised and unresectable neuroblastoma in infants: excellent outcome with primary chemotherapy. Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique. Med Pediatr Oncol. 2001; 36(1):247-50. DOI: 10.1002/1096-911X(20010101)36:1<247::AID-MPO1061>3.0.CO;2-Z. View

10.

Rubie H, Hartmann O, Michon J, Frappaz D, Coze C, Chastagner P . N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique. J Clin Oncol. 1997; 15(3):1171-82. DOI: 10.1200/JCO.1997.15.3.1171. View

11.

Kulkarni K, Marwaha R . Outcome of neuroblastoma in India. Indian J Pediatr. 2013; 80(10):832-7. DOI: 10.1007/s12098-012-0948-9. View

12.

George R, London W, Cohn S, Maris J, Kretschmar C, Diller L . Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 2005; 23(27):6466-73. DOI: 10.1200/JCO.2005.05.582. View

13.

Cozzi D, Mele E, Ceccanti S, Natale F, Clerico A, Schiavetti A . Long-term follow-up of the "wait and see" approach to localized perinatal adrenal neuroblastoma. World J Surg. 2012; 37(2):459-65. DOI: 10.1007/s00268-012-1837-0. View

14.

Bagatell R, Beck-Popovic M, London W, Zhang Y, Pearson A, Matthay K . Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J Clin Oncol. 2008; 27(3):365-70. PMC: 2651034. DOI: 10.1200/JCO.2008.17.9184. View

15.

Nakagawa A, Matsuoka K, Okita H, Iwafuchi H, Hori H, Kumagai M . Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology. Pediatr Dev Pathol. 2011; 14(2):87-92. DOI: 10.2350/08-12-0579.1. View

16.

Hero B, Simon T, Spitz R, Ernestus K, Gnekow A, Scheel-Walter H . Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol. 2008; 26(9):1504-10. DOI: 10.1200/JCO.2007.12.3349. View

17.

Yamamoto K, Hanada R, Kikuchi A, Ichikawa M, Aihara T, Oguma E . Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol. 1998; 16(4):1265-9. DOI: 10.1200/JCO.1998.16.4.1265. View

18.

Bowman L, Castleberry R, Cantor A, Joshi V, Cohn S, SMITH E . Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst. 1997; 89(5):373-80. DOI: 10.1093/jnci/89.5.373. View

19.

Fritsch P, Kerbl R, Lackner H, Urban C . "Wait and see" strategy in localized neuroblastoma in infants: an option not only for cases detected by mass screening. Pediatr Blood Cancer. 2004; 43(6):679-82. DOI: 10.1002/pbc.20126. View

20.

Gigliotti A, Di Cataldo A, Sorrentino S, Parodi S, Rizzo A, Buffa P . Neuroblastoma in the newborn. A study of the Italian Neuroblastoma Registry. Eur J Cancer. 2009; 45(18):3220-7. DOI: 10.1016/j.ejca.2009.08.020. View